#sexually transmitted infection

Highlights from the research presented at the 9th International AIDS Society Conference on HIV Science in Paris.

Rally to save health care as Congress returns to DC on Sept 6. It’s also HIV/STD Action Day—here’s what you can do.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

A look at a group of 13- to 24-year-olds on antiretrovirals found one in six episodically had a significant viral load and an STI.

In a British study, men on PrEP also reported many psychosocial benefits to using Truvada for prevention.

Going on PrEP was also linked to a modest increase in STI diagnoses, but the shift was not statistically significant.

The vaccine may inform future research into a gonorrhea-specific vax.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

With three identified cases, in Japan, France and Spain, proving untreatable, the World Health Organization has issued a call to action.

The $25 fee could deter people from getting tested in Mississippi, where HIV and STI rates are high.

HIV prevention efforts would also take a huge hit under Trump’s draconian proposed budget cuts and the House health care bill.

This bill does not put funding for domestic HIV programs where it needs to be, but it’s a step in the right direction.

Congress is expected to approve more funding for AIDS housing but cut some of the Ryan White program.

A recent study looks at the perspectives of these PrEP-prescribing clinicians.

In Houston, some pharmacies will also begin prescribing Truvada as PrEP on-site.